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Prostate cancer is the second most common male malig-
nancy worldwide with a wide spectrum of biological
behaviour ranging from fairly indolent disease to highly
aggressive metastatic castrate resistant tumours. In the
past decade there have been advances in therapies for
treating advanced and recurrent prostate cancer and
improved diagnostic/prognostic tools are required to
refine the therapeutic approach at various stages in the
management of prostate cancer patients.
For tumour staging/lesion localisation multiparametric
prostate MRI is the modality of choice. Several PET tra-
cers are proving more sensitive than conventional imaging
techniques for early detection of lymph node and bone
metastases. However a general limitation of PET is the
spatial resolution which limits the reliability for detection
of small lesions.
The use of F-18 fluoro-deoxyglucose (FDG) PET/CT
in prostate cancer has been disappointing largely due to
the fact that many prostate cancers have only low level
glucose metabolism.
C-11/F-18 choline, markers of cell membrane metabo-
lism, are now widely used in Europe and in certain UK
centres particularly in the scenario of biochemical relapse
and high risk staging with equivocal findings on conven-
tional work-up [1-3]. However, in cases of biochemical
relapse with low PSA rise and low PSA velocity, choline
PET has low detection rates [4].
Prostate specific membrane antigen (PSMA), a cell sur-
face membrane glycoprotein, is a promising target for the
diagnosis and treatment of prostate cancer. Recently Ga-68
radiolabelled ligand targeted to PSMA has been introduced
to a few European centres. Early data suggests this may be
more sensitive than choline PET/CT in patients with bio-
chemical failure and low PSA [5-7]. In addition it offers the
opportunity for Lu-177 or Y-90 targeted radionuclide
therapy.
F-18 sodium fluoride (NaF) is highly sensitive com-
pared to bone scintigraphy with Tc99m labelled phos-
phates but only assess skeletal disease [8].
Other PET tracers being explored include C-11 acetate
targeting lipogenesis, tracers radiolabelling bombesin and
targeting gastrin-releasing peptide receptor (GRPR), amino
acid transport with anti-1-amino-3-F18-fluorocyclobutane-
1-carboxylic acid (FACBC ) and F-18-fluoro-5a-dihydro-
testosterone (FDHT) targeting the androgen receptor
[9,10].
This talk reviews the diagnostic utility of PET in pros-
tate cancer.
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